Original
Rivaroxaban frente al tratamiento estándar en la prevención del tromboembolismo venoso tras artroplastia de cadera o rodilla en la práctica clínica diaria (datos de España del estudio internacional XAMOS)
Rivaroxaban versus standard of care in venous thromboembolism prevention following hip or knee arthroplasty in daily clinical practice (Spanish data from the international study XAMOS)
J. Graneroa,
, P. Díaz de Radab, L.M. Lozanoc, J. Martínezd, A. Herrerae, en nombre de los investigadores del grupo XAMOS España ◊
Autor para correspondencia
a Departamento de Cirugía Ortopédica y Traumatología, Hospital Germans Trias i Pujol, Badalona, Barcelona, España
b Departamento de Cirugía Ortopédica y Traumatología, Clínica Universitaria de Navarra, Pamplona, España
c Departamento de Cirugía Ortopédica y Traumatología, Hospital Clínic i Provincial, Barcelona, España
d Departamento de Cirugía Ortopédica y Traumatología, Hospital de Alcorcón, Alcorcón, Madrid, España
e Departamento de Cirugía Ortopédica y Traumatología. Hospital Miguel Servet, Zaragoza, España
Leído
4277
Vecesse ha leído el artículo
762
Total PDF
3515
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 94 | 24 | 118 |
| 2025 11 | 50 | 36 | 86 |
| 2025 10 | 71 | 12 | 83 |
| 2025 9 | 36 | 16 | 52 |
| 2025 8 | 54 | 11 | 65 |
| 2025 7 | 67 | 8 | 75 |
| 2025 6 | 52 | 21 | 73 |
| 2025 5 | 46 | 5 | 51 |
| 2025 4 | 52 | 3 | 55 |
| 2025 3 | 72 | 12 | 84 |
| 2025 2 | 60 | 5 | 65 |
| 2025 1 | 30 | 4 | 34 |
| 2024 12 | 61 | 4 | 65 |
| 2024 11 | 49 | 4 | 53 |
| 2024 10 | 61 | 4 | 65 |
| 2024 9 | 75 | 15 | 90 |
| 2024 8 | 56 | 10 | 66 |
| 2024 7 | 61 | 6 | 67 |
| 2024 6 | 45 | 6 | 51 |
| 2024 5 | 39 | 9 | 48 |
| 2024 4 | 32 | 12 | 44 |
| 2024 3 | 45 | 5 | 50 |
| 2024 2 | 60 | 12 | 72 |
| 2024 1 | 55 | 4 | 59 |
| 2023 12 | 44 | 14 | 58 |
| 2023 11 | 54 | 14 | 68 |
| 2023 10 | 73 | 19 | 92 |
| 2023 9 | 43 | 6 | 49 |
| 2023 8 | 52 | 11 | 63 |
| 2023 7 | 65 | 9 | 74 |
| 2023 6 | 51 | 8 | 59 |
| 2023 5 | 82 | 4 | 86 |
| 2023 4 | 69 | 19 | 88 |
| 2023 3 | 50 | 8 | 58 |
| 2023 2 | 76 | 8 | 84 |
| 2022 1 | 46 | 11 | 57 |
| 2022 12 | 52 | 19 | 71 |
| 2022 11 | 84 | 14 | 98 |
| 2022 10 | 123 | 15 | 138 |
| 2022 9 | 50 | 24 | 74 |
| 2022 8 | 53 | 10 | 63 |
| 2022 7 | 49 | 11 | 60 |
| 2022 6 | 40 | 7 | 47 |
| 2022 5 | 56 | 12 | 68 |
| 2022 4 | 49 | 22 | 71 |
| 2022 3 | 53 | 11 | 64 |
| 2022 2 | 37 | 11 | 48 |
| 2021 1 | 46 | 11 | 57 |
| 2021 12 | 38 | 12 | 50 |
| 2021 11 | 80 | 13 | 93 |
| 2021 10 | 74 | 18 | 92 |
| 2021 9 | 43 | 13 | 56 |
| 2021 8 | 55 | 10 | 65 |
| 2021 7 | 33 | 20 | 53 |
| 2021 6 | 32 | 13 | 45 |
| 2021 5 | 59 | 14 | 73 |
| 2021 4 | 150 | 18 | 168 |
| 2021 3 | 65 | 12 | 77 |
| 2021 2 | 31 | 9 | 40 |
| 2020 1 | 26 | 11 | 37 |
| 2020 12 | 2 | 0 | 2 |
| 2020 4 | 4 | 2 | 6 |
| 2020 1 | 2 | 2 | 4 |
| 2019 10 | 13 | 2 | 15 |
| 2019 6 | 1 | 2 | 3 |
| 2019 3 | 1 | 2 | 3 |
| 2018 10 | 2 | 0 | 2 |
| 2018 6 | 1 | 0 | 1 |
| 2018 3 | 1 | 0 | 1 |
| 2018 2 | 11 | 2 | 13 |
| 2018 1 | 10 | 2 | 12 |
| 2017 12 | 1 | 0 | 1 |
| 2017 7 | 1 | 0 | 1 |
| 2017 6 | 1 | 0 | 1 |
| 2017 5 | 2 | 0 | 2 |
| 2017 4 | 1 | 0 | 1 |
| 2017 2 | 1 | 0 | 1 |
| 2016 1 | 2 | 0 | 2 |
| 2016 12 | 2 | 2 | 4 |
| 2016 11 | 0 | 1 | 1 |
| 2016 10 | 0 | 3 | 3 |
| 2016 9 | 1 | 0 | 1 |
| 2016 8 | 2 | 1 | 3 |
| 2016 6 | 3 | 4 | 7 |
| 2016 5 | 3 | 1 | 4 |
| 2016 4 | 11 | 8 | 19 |
| 2016 3 | 2 | 5 | 7 |
| 2016 2 | 12 | 6 | 18 |
| 2015 1 | 15 | 8 | 23 |
| 2015 12 | 1 | 0 | 1 |
Mostrar todo
